監修

  • 谷口 浩也先生

    愛知県がんセンター中央病院
    薬物療法部 医長

  • 加藤 健先生

    国立がん研究センター中央病院 消化管内科 医長

  • 山﨑 健太郎先生

    静岡県立静岡がんセンター
    消化器内科 医長

レポーター (50音順)

  • 新井 裕之先生

    聖マリアンナ医科大学
    臨床腫瘍学 診療助手

  • 川上 尚人先生

    近畿大学医学部
    内科学腫瘍内科部門 医学部講師

  • 中島 雄一郎先生

    九州大学大学院
    消化器・総合外科 助教

  • 成田 有季哉先生

    愛知県がんセンター中央病院
    薬物療法部 医長

  • 宮本 敬大先生

    国立がん研究センター中央病院
    消化管内科 がん専門修練医

  • 山田 武史先生

    筑波大学附属病院
    消化器内科 病院講師

2017年6月2日~6日に米国シカゴで開催された、米国臨床腫瘍学会年次集会(2017 Annual Meeting of the American Society of Clinical Oncology®)より、大腸癌や胃癌などの消化器癌の注目演題のレポートをお届けします。臨床研究の第一線で活躍するドクターにより執筆、監修されたレポートを楽しみにしてください。

更新履歴

Live Short Cuts

演題レポート

Colorectal Cancer

Oral Abstract #3503
大腸癌

Primary tumor location is an independent prognostic marker from molecular features for overall survival in patients with metastatic colorectal cancer: Analysis of CALGB/SWOG 80405 (Alliance).

Alan P. Venook, et al.

Oral Abstract #LBA1
大腸癌

Prospective pooled analysis of six phase III trials investigating duration of adjuvant Oxaliplatin-based therapy (3 vs. 6 months) for patients with stage III colon cancer: The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.

Qian Shi, et al.

Oral Abstract #3505
大腸癌

Randomized trial of Irinotecan and Cetuximab with or without Vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)

Scott Kopetz, et al.

Poster Abstract #3531
大腸癌

Combination of Nivolumab (NIVO) + Ipilimumab (IPI) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR) / high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study

Thierry André, et al.

Oral Abstract #3002
大腸癌

Phase I studies of the novel carcinoembryonic antigen CD3 T-cell bispecific (CEA-TCB) antibody as a single agent and in combination with atezolizumab: preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC)

Josep Tabernero, et al.

Oral Abstract #3506
大腸癌

SUNSHINE: Randomized double-blind phase II trial of vitamin D supplementation in patients with previously untreated metastatic colorectal cancer

Kimmie NG, et al.

Poster Abstract #3540
大腸癌

Regorafenib (REG) versus trifluridine/tipiracil (TAS-102) as salvage-line in patients with metastatic colorectal cancer refractory to standard chemotherapies: a propensity score analysis from a multicenter observational study (REGOTAS)

Shota Fukuoka, et al.

Poster Abstract #3518
大腸癌

Comparison of long-term survival outcomes between laparoscopic and open surgery for mid or low rectal cancer treated with preoperative chemoradiotherapy: 7-year follow-up of COREAN trial.

Ji Won Park, et al.

Non-Colorectal Cancer

Oral Abstract #4004
胃癌

Perioperative chemotherapy with Docetaxel, Oxaliplatin, and Fluorouracil/Leucovorin (FLOT) versus Epirubicin, Cisplatin, and Fluorouracil or Capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4): A multicenter, randomized phase 3 trial.

Al-Batran SE, et al.

Oral Abstract #4001
肝細胞癌

A phase 3 trial of Lenvatinib vs Sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma (REFLECT study)

Ann Lii Cheng, et al.

Oral Abstract #4014
胃癌

Nivolumab±Ipilimumab in patients with advanced/metastatic chemotherapy-refractory gastric, esophageal, or gastroesophageal junction cancer: CheckMate 032 study

Yelena Y. Janjigian, et al.

Poster Abstract #4059
胃癌

A phase II study (KSCC/HGCSG/CCOG/PerSeUS1501B) of trastuzumab plus S-1 and oxaliplatin for HER2-positive advanced gastric cancer

Katsunori Shinozaki, et al.

Poster Abstract #4010
胃癌

ABSOLUTE, a phase 3 trial of nanoparticle albumin-bound paclitaxel (nab-PTX) versus solvent-based paclitaxel (sb-PTX) in patients with pre-treated advanced gastric cancer (AGC): Efficacy and QOL results

Keisuke Koeda, et al.

©ASCO/Danny Morton 2017

©ASCO/Scott Morgan 2017

©ASCO/Todd Buchanan 2017

©ASCO/Todd Buchanan 2017